CELLF-BIO LLC
Biotech · Private
Bioengineered internal anal sphincter (BioSphincter) constructed from patient's own cells for implantation to restore fecal continence
- Grants
- $11M
- 9 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 1
- 0 granted · 1 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20152016201720182019202020212022
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase II · Implantation of Bioengineered Intrinsically Innervated Internal Anal Sphincter (BioSphincter) to Treat Fecal Incontinence | $225,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Implantation of Bioengineered Intrinsically Innervated Internal Anal Sphincter (BioSphincter) to Treat Fecal Incontinence | $550,134 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase II · Implantation of Bioengineered Intrinsically Innervated Internal Anal Sphincter BioSphincter to Treat Fecal Incontinence | $1,174,055 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase II · Implantation of Bioengineered Intrinsically Innervated Internal Anal Sphincter (BioSphincter) to Treat Fecal Incontinence | $27,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Implantation of Bioengineered Intrinsically Innervated Internal Anal Sphincter (BioSphincter) to Treat Fecal Incontinence | $596,921 | |
| Federal grant | Department of Health and Human Services · Phase II · BioSphincter to Treat Fecal Incontinence. Phase 1/2 Clinical Trial. SBIR Phase IIB | $1,284,815 | |
| Federal grant | Department of Health and Human Services · Phase II · BioSphincter to Treat Fecal Incontinence. Phase 1/2 Clinical Trial. SBIR Phase IIB | $4,072,067 | |
| Federal grant | Department of Health and Human Services · Phase II · BioSphincter to Treat Fecal Incontinence. Phase 1/2 Clinical Trial. SBIR Phase IIB | $1,393,626 | |
| Federal grant | Department of Health and Human Services · Phase II · BioSphincter to Treat Fecal Incontinence. Phase 1/2 Clinical Trial. SBIR Phase IIB | $1,393,626 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2243 | Acelyrin | — | — |
| 2244 | Cour Pharmaceutical | — | — |
| 2245 | AVEXEGEN THERAPEUTICS INC. | — | — |
| 2246 | CELLF-BIO LLC | — | — |
| 2247 | NOUR HEART, INC. | — | — |
| 2248 | NAPROGENIX, INC. | — | — |
| 2249 | BRIDGENE BIOSCIENCES, INC. | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Bioengineered Internal Anal Sphincter Constructs And Methods Of Use Thereofapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.